MASS SPECTROMETRY & ANALYTICAL PHARMACOLOGY SHARED RESOURCE: PROJECT SUMMARY In 2021, the Proteomics & Metabolomics Shared Resource (PMSR), which had been Cancer Center Support Grant (CCSG)–funded since 2009, was reorganized to form the Mass Spectrometry & Analytical Pharmacology Shared Resource (MSAPSR) with the inclusion of new mass spectrometry imaging (MSI), pharmacokinetic (PK), and pharmacodynamics (PD) capabilities at the NJ site. The MSAPSR functions under a collaborative model organized into four essential components: (1) proteomics, (2) metabolomics, (3) molecular imaging, and (4) PK/PD applications. The creation of MSAPSR affords Georgetown Lombardi Comprehensive Cancer Center (LCCC) Members seamless access to cutting-edge technical expertise, services, and technologies across the consortium. MSAPSR is co-directed by Claire Carter, PhD (NJ), Junfeng Ma, PhD (DC) and Amrita Cheema, PhD (DC), and is supported by five staff members and two faculty members with expertise in sample preparation, experimental design, data acquisition and data analysis. Supported by $6.9M in institutional investment since 2019, MSAPSR houses multiple state-of-the-art instruments across both campuses to provide: (1) routine and advanced MS -based proteomic studies for the identification of proteins and peptides, and the characterization of post-translational modifications (phosphorylation, acetylation, O-GlcNAcylation) and quantification (iTRAQ); (2) multiplex and spatial imaging of protein markers at the subcellular level using imaging mass cytometry (IMC) for cancer cells and immune cells in tissue sections; (3) comprehensive metabolomic and lipidomic profiling and quantitation, through the utilization of over a dozen in-house developed and validated MS-based assays; (4) real-time cellular metabolic flux and respiration analysis using the Seahorse Extracellular Flux Analyzer; (5) MSI to allow untargeted label-free imaging of lipids, metabolites, glycans, peptides and pharmaceuticals within tissue sections and 3D organoid/spheroid models; and (6) support for drug development pipelines through MS-based PK and PD investigations. The MSAPSR receives input from the Advisory Committee and annual user surveys to prioritize development and assess programmatic needs across the Consortium. To this end, the individual components of the MSAPSR augment basic, clinical, translational, and population science cancer research by providing access to the expertise and instrumentation for a wide spectrum of MS- based molecular phenotyping services. Taken together, these components support systems biology understanding of the interplay between pathways that drive cancer development, aggression, metastatic disease, resistance to therapy and therapeutic efficacy. In FY2022, the MSAPSR provided services to 28 LCCC Members across all three LCCC Research Programs (10 Cancer Cell Biology Members, 16 Cancer Host Interactions Members, and 2 Cancer Prevention and Control Members). During ...